UPS downgraded by Stifel: Investments could limit earnings growth next year

FAN Editor

A UPS driver loads packages to be delivered onto a dolly from a United Parcel Service (UPS) all-electric vehicle in Sacramento, California, U.S.,

Ken James | Bloomberg | Getty Images

After a strong move upward for UPS’s stock on the back of better-than-expected earnings, Stifel said more upside will take time.

The firm downgraded the stock to hold from buy and maintained its $118 per share price target, as it does not feel comfortable pushing the valuation multiple up high enough to maintain its buy rating.

“Given the company spoke on its earnings call of a challenging macro environment heading into year-end and that we believe its long-term initiatives will likely require extra investment in 2020 that could limit margin expansion and earnings growth next year, we are stepping to the sidelines with respect to the stock,” said Stifel’s David Ross in a note to client on Sunday.

Shares of the world’s largest package delivery company soared more than 9% last week after UPS reported better-than-expected second-quarter earnings, driven by high demand for Next Day Air. UPS has been investing billions of dollars to make a faster and more efficient network and Ross said although the investments working well for the company and the stock, the spending will prevent margins from expanding in the near-term.

Shares of UPS fell more than 1% in premarket trading on Monday.

Ross said that fears about e-commerce giant Amazon are “somewhat overblown,” as Amazon seems to be adding to the network density for UPS. However, Ross said this could change.

“Over time, the picture will change and Amazon could become more of a competitor than a customer, but for the next couple years at least, we see UPS helping Amazon more than pushing them away,” said Ross.

Shares of UPS are up more than 23% so far this year.

— with reporting from CNBC’s Michael Bloom

Free America Network Articles

Leave a Reply

Next Post

Stocks making the biggest moves premarket: Pfizer, Mylan, BlackRock, Domino's & more

Check out the companies making headlines before the bell: Pfizer — Pfizer is merging its off-patent drug unit with Mylan in a stock swap deal to form a new entity, to be 43% owned by Mylan shareholders with Pfizer shareholders owning the rest. Separately, Pfizer reported adjusted quarterly profit of […]